Christina L Jablonski1, Samuel Ferguson2, Ambra Pozzi3, Andrea L Clark4. 1. Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada. Electronic address: cljablon@ucalgary.ca. 2. Faculty of Science, University of Victoria, Victoria, BC, Canada. Electronic address: samferg@uvic.ca. 3. Department of Medicine, Vanderbilt University, Nashville, TN, USA; Department of Medicine, Veterans Affairs Hospital, Nashville, TN, USA. Electronic address: ambra.pozzi@vanderbilt.edu. 4. Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada; Department of Surgery, Faculty of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: alclark@kin.ucalgary.ca.
Abstract
BACKGROUND/ PURPOSE: The goal of this study was to determine the role of the collagen binding receptor integrin α1β1 in regulating osmotically induced [Ca(2+)]i transients in chondrocytes. METHOD: The [Ca(2+)]i transient response of chondrocytes to osmotic stress was measured using real-time confocal microscopy. Chondrocytes from wildtype and integrin α1-null mice were imaged ex vivo (in the cartilage of intact murine femora) and in vitro (isolated from the matrix, attached to glass coverslips). Immunocytochemistry was performed to detect the presence of the osmosensor, transient receptor potential vanilloid-4 (TRPV4), and the agonist GSK1016790A (GSK101) was used to test for its functionality on chondrocytes from wildtype and integrin α1-null mice. RESULTS/ INTERPRETATION: Deletion of the integrin α1 subunit inhibited the ability of chondrocytes to respond to a hypo-osmotic stress with [Ca(2+)]i transients ex vivo and in vitro. The percentage of chondrocytes responding ex vivo was smaller than in vitro and of the cells that responded, more single [Ca(2+)]i transients were observed ex vivo compared to in vitro. Immunocytochemistry confirmed the presence of TRPV4 on wildtype and integrin α1-null chondrocytes, however application of GSK101 revealed that TRPV4 could be activated on wildtype but not integrin α1-null chondrocytes. Integrin α1β1 is a key participant in chondrocyte transduction of a hypo-osmotic stress. Furthermore, the mechanism by which integrin α1β1 influences osmotransduction is independent of matrix binding, but likely dependent on the chondrocyte osmosensor TRPV4.
BACKGROUND/ PURPOSE: The goal of this study was to determine the role of the collagen binding receptor integrin α1β1 in regulating osmotically induced [Ca(2+)]i transients in chondrocytes. METHOD: The [Ca(2+)]i transient response of chondrocytes to osmotic stress was measured using real-time confocal microscopy. Chondrocytes from wildtype and integrin α1-null mice were imaged ex vivo (in the cartilage of intact murine femora) and in vitro (isolated from the matrix, attached to glass coverslips). Immunocytochemistry was performed to detect the presence of the osmosensor, transient receptor potential vanilloid-4 (TRPV4), and the agonist GSK1016790A (GSK101) was used to test for its functionality on chondrocytes from wildtype and integrin α1-null mice. RESULTS/ INTERPRETATION: Deletion of the integrin α1 subunit inhibited the ability of chondrocytes to respond to a hypo-osmotic stress with [Ca(2+)]i transients ex vivo and in vitro. The percentage of chondrocytes responding ex vivo was smaller than in vitro and of the cells that responded, more single [Ca(2+)]i transients were observed ex vivo compared to in vitro. Immunocytochemistry confirmed the presence of TRPV4 on wildtype and integrin α1-null chondrocytes, however application of GSK101 revealed that TRPV4 could be activated on wildtype but not integrin α1-null chondrocytes. Integrin α1β1 is a key participant in chondrocyte transduction of a hypo-osmotic stress. Furthermore, the mechanism by which integrin α1β1 influences osmotransduction is independent of matrix binding, but likely dependent on the chondrocyte osmosensor TRPV4.
Authors: Jun-Tzu Chao; Peichun Gui; Gerald W Zamponi; George E Davis; Michael J Davis Journal: Am J Physiol Cell Physiol Date: 2010-12-22 Impact factor: 4.249
Authors: Kristopher Clark; Michiel Langeslag; Bart van Leeuwen; Leonie Ran; Alexey G Ryazanov; Carl G Figdor; Wouter H Moolenaar; Kees Jalink; Frank N van Leeuwen Journal: EMBO J Date: 2006-01-12 Impact factor: 11.598
Authors: Nicole Alessandri-Haber; Olayinka A Dina; Elizabeth K Joseph; David B Reichling; Jon D Levine Journal: J Neurosci Date: 2008-01-30 Impact factor: 6.167
Authors: Kevin S Thorneloe; Anthony C Sulpizio; Zuojun Lin; David J Figueroa; Angela K Clouse; Gerald P McCafferty; Tim P Chendrimada; Erin S R Lashinger; Earl Gordon; Louise Evans; Blake A Misajet; Douglas J Demarini; Josephine H Nation; Linda N Casillas; Robert W Marquis; Bartholomew J Votta; Steven A Sheardown; Xiaoping Xu; David P Brooks; Nicholas J Laping; Timothy D Westfall Journal: J Pharmacol Exp Ther Date: 2008-05-22 Impact factor: 4.030
Authors: Mimi N Phan; Holly A Leddy; Bartholomew J Votta; Sanjay Kumar; Dana S Levy; David B Lipshutz; Suk Hee Lee; Wolfgang Liedtke; Farshid Guilak Journal: Arthritis Rheum Date: 2009-10
Authors: Tim W G M Spitters; Carlos M D Mota; Samuel C Uzoechi; Barbara Slowinska; Dirk E Martens; Lorenzo Moroni; Marcel Karperien Journal: Tissue Eng Part A Date: 2014-12 Impact factor: 3.845
Authors: Minjie Zhang; Sriniwasan B Mani; Yao He; Amber M Hall; Lin Xu; Yefu Li; David Zurakowski; Gregory D Jay; Matthew L Warman Journal: J Clin Invest Date: 2016-07-18 Impact factor: 14.808
Authors: Vittorio Abbonante; Christian Andrea Di Buduo; Cristian Gruppi; Carmelo De Maria; Elise Spedden; Aurora De Acutis; Cristian Staii; Mario Raspanti; Giovanni Vozzi; David L Kaplan; Francesco Moccia; Katya Ravid; Alessandra Balduini Journal: Haematologica Date: 2017-04-14 Impact factor: 9.941